Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionAssetmark, Inc
Latest Disclosed Ownership166,617 shares
Latest Disclosed Value $ 10,768,457
Assetmark, Inc reports 21.25% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On May 6, 2026 - Assetmark, Inc filed a 13F-HR form disclosing ownership of 166,617 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $10,768,457 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 137,415 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 21.25% during the quarter. The current value of the position is $11,633,199 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 166,617 29,202 21.25 10,768 16.44 0.0220
2026-01-23 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 137,415 14,568 11.86 9,248 2.65 0.0189
2025-11-06 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 122,847 1,309 1.08 9,010 42.50 0.0193
2025-08-04 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 121,538 15,567 14.69 6,322 -6.51 0.0149
2025-05-06 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 105,971 3,200 3.11 6,762 37.63 0.0186
2025-02-06 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 102,771 9,612 10.32 4,913 -7.86 0.0133
2024-11-01 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 93,159 8,385 9.89 5,332 20.14 0.0153
2024-08-13 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 84,774 -23,174 -21.47 4,439 1.07 0.0137
2024-05-07 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 107,948 2,756 2.62 4,391 12.97 0.0143
2024-02-09 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 105,192 43,706 71.08 3,888 65.55 0.0140
2023-10-27 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 61,486 -16,469 -21.13 2,349 -16.47 0.0094
2023-08-11 2023-06-30 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 77,955 40,263 106.82 2,812 95.34 0.0110
2023-05-05 2023-03-31 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 37,692 8,366 28.53 1,439 -13.73 0.0060
2023-02-10 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 29,326 3,876 15.23 1,669 65.81 0.0072
2022-11-01 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 25,450 23,270 1,067.43 1,006 947.92 0.0047
2022-08-03 2022-06-30 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 2,180 835 62.08 96 77.78 0.0004
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 1,345 -61 -4.34 54 -5.26 0.0002
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 1,406 51 3.76 57 3.64 0.0002
2021-11-12 2021-09-30 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 1,355 120 9.72 55 -1.79 0.0002
2021-08-16 2021-06-30 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 1,235 0 0.00 56 9.80 0.0003
2021-05-14 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,235 305 32.80 51 27.50 0.0003
2021-02-10 2020-12-31 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 930 930 40 0.0002
2017-09-14 2016-03-31 13F/A-1 HALOZYME THERAPEUTICS INC COM COM 40637H109 0 -15 -100.00 0 0.0000
2017-09-14 2015-12-31 13F/A-1 HALOZYME THERAPEUTICS INC COM COM 40637H109 15 15 0 0.0000
2016-02-12 2015-12-31 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 15 15 0
2015-11-10 2015-09-30 13F HALOZYME THERAPEUTICS INC COM COM 40637H109 0 0 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.